Clinical effects of gliclazide sustained-release tablets on type 2 diabetes mellitus / 中国基层医药

ABSTRACT

Objective To investigate the clinical effects of gliclazide sustained-release tablet for recently diag-nosed type 2 diabetes mellitus. Methods 118 subjects with recently diagnosed type 2 diabetes and normal figure were divided into three groups. The three group subjects used gliclazide sustained-release tablet, repaglinide(import-ed) ,novolin 30R for 12 weeks,respectively. For all pretherapy and post-treatment cases, blood glucose and glycosy-lated hemoglobin were tested before meal. After two hours of meal, blood glucose was tested again. Meanwhile, hypo-glycaemia event was inspected. The test results were analyzed by "mean ± standard deviation" method. Results There are no significant difference(P>0.05) in fasting blood sugar and postprandial blood sugar(2h) level between the group using gliclazide sustained-release tablet and the group using novolin 30R. The clinical effects of both gli-clazide sustained-release tablet and novolin 30R to fasting blood sugar are all better than that of repaglinide(import-ed) (P < 0.01). But there are no significant difference in postprandial blood sugar(2h) level between the group of us-ing gliclazide sustained-release tablet and the following two group repaglinide(imported) and novolin 30R. Conclu-sion The investigation results show that gliclazide sustained-release tablet is better than repaglinide(imported) in fasting blood sugar. But for the effects of postprandial blood sugar(2h), there is no significant difference between gli-clazide sustained-release tablet, repaglinide(imported) and novolin 30R.